Review Article| Volume 37, ISSUE 1, P183-202, February 2023

Multidisciplinary Management of Brain Metastasis from Breast Cancer


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Hematology/Oncology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Sun M.S.
        • Yun Y.Y.
        • Liu H.J.
        • et al.
        Brain metastases in de novo breast cancer: An updated population-level study from SEER database.
        Asian J Surg. 2022;
        • Parkes A.
        • Clifton K.
        • Al-Awadhi A.
        • et al.
        Characterization of bone only metastasis patients with respect to tumor subtypes.
        NPJ Breast Cancer. 2018; 4: 2
        • Leone J.P.
        • Leone B.A.
        Breast cancer brain metastases: the last frontier.
        Exp Hematol Oncol. 2015; 4: 33
        • van den Bent M.J.
        Management of metastatic (parenchymal, leptomeningeal, and epidural) lesions.
        Curr Opin Oncol. 2004; 16: 309-313
        • Ferraro E.
        • Singh J.
        • Patil S.
        • et al.
        Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab.
        NPJ Breast Cancer. 2022; 8: 37
        • Dano D.
        • Lardy-Cleaud A.
        • Monneur A.
        • et al.
        Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME).
        ESMO Open. 2021; 6: 100220
        • Garber H.R.
        • Raghavendra A.S.
        • Lehner M.
        • et al.
        Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer.
        NPJ Breast Cancer. 2022; 8: 46
        • Sperduto P.W.
        • Mesko S.
        • Li J.
        • et al.
        Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today.
        Int J Radiat Oncol Biol Phys. 2020; 107: 334-343
      1. Graded Prognostic Assessment (GPA) tool.
        (Available at:) (Accessed July 5, 2022)
        • Franzoi M.A.
        • Hortobagyi G.N.
        Leptomeningeal carcinomatosis in patients with breast cancer.
        Crit Rev Oncol Hematol. 2019; 135: 85-94
        • O'Phelan K.H.
        • Bunney E.B.
        • Weingart S.D.
        • et al.
        Emergency neurological life support: spinal cord compression (SCC).
        Neurocrit Care. 2012; 17: S96-S101
        • Yanez M.L.
        • Miller J.J.
        • Batchelor T.T.
        Diagnosis and treatment of epidural metastases.
        Cancer. 2017; 123: 1106-1114
        • O'Brown N.M.
        • Pfau S.J.
        • Gu C.
        Bridging barriers: a comparative look at the blood-brain barrier across organisms.
        Genes Dev. 2018; 32: 466-478
        • Cosgrove N.
        • Vareslija D.
        • Keelan S.
        • et al.
        Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities.
        Nat Commun. 2022; 13: 514
        • Jiang B.
        • Mu Q.
        • Qiu F.
        • et al.
        Machine learning of genomic features in organotropic metastases stratifies progression risk of primary tumors.
        Nat Commun. 2021; 12: 6692
        • Strickland M.R.
        • Alvarez-Breckenridge C.
        • Gainor J.F.
        • et al.
        Tumor Immune Microenvironment of Brain Metastases: Toward Unlocking Antitumor Immunity.
        Cancer Discov. 2022; 12: 1199-1216
        • Blazquez R.
        • Wlochowitz D.
        • Wolff A.
        • et al.
        PI3K: A master regulator of brain metastasis-promoting macrophages/microglia.
        Glia. 2018; 66: 2438-2455
        • Abbott N.J.
        • Patabendige A.A.
        • Dolman D.E.
        • et al.
        Structure and function of the blood-brain barrier.
        Neurobiol Dis. 2010; 37: 13-25
        • Arvanitis C.D.
        • Ferraro G.B.
        • Jain R.K.
        The blood-brain barrier and blood-tumour barrier in brain tumours and metastases.
        Nat Rev Cancer. 2020; 20: 26-41
        • Steeg P.S.
        The blood-tumour barrier in cancer biology and therapy.
        Nat Rev Clin Oncol. 2021; 18: 696-714
        • Kaal E.C.
        • Taphoorn M.J.
        • Vecht C.J.
        Symptomatic management and imaging of brain metastases.
        J Neurooncol. 2005; 75: 15-20
        • Cagney D.N.
        • Martin A.M.
        • Catalano P.J.
        • et al.
        Implications of Screening for Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer.
        JAMA Oncol. 2018; 4: 1001-1003
        • Farris M.
        • McTyre E.R.
        • Cramer C.K.
        • et al.
        Brain Metastasis Velocity: A Novel Prognostic Metric Predictive of Overall Survival and Freedom From Whole-Brain Radiation Therapy After Distant Brain Failure Following Upfront Radiosurgery Alone.
        Int J Radiat Oncol Biol Phys. 2017; 98: 131-141
        • Rajpurohit A.
        • Purandare N.
        • Moiyadi A.
        • et al.
        Multidisciplinary brain metastasis clinic: is it effective and worthwhile?.
        Ecancermedicalscience. 2020; 14: 1136
        • McKee M.J.
        • Keith K.
        • Deal A.M.
        • et al.
        A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience.
        Oncologist. 2016; 21: 16-20
        • Patchell R.A.
        • Tibbs P.A.
        • Walsh J.W.
        • et al.
        A randomized trial of surgery in the treatment of single metastases to the brain.
        N Engl J Med. 1990; 322: 494-500
        • Vecht C.J.
        • Haaxma-Reiche H.
        • Noordijk E.M.
        • et al.
        Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?.
        Ann Neurol. 1993; 33: 583-590
        • Mintz A.H.
        • Kestle J.
        • Rathbone M.P.
        • et al.
        A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis.
        Cancer. 1996; 78: 1470-1476
        • Brown P.D.
        • Ballman K.V.
        • Cerhan J.H.
        • et al.
        Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial.
        Lancet Oncol. 2017; 18: 1049-1060
        • Agboola O.
        • Benoit B.
        • Cross P.
        • et al.
        Prognostic factors derived from recursive partition analysis (RPA) of Radiation Therapy Oncology Group (RTOG) brain metastases trials applied to surgically resected and irradiated brain metastatic cases.
        Int J Radiat Oncol Biol Phys. 1998; 42: 155-159
        • Ng P.R.
        • Choi B.D.
        • Aghi M.K.
        • et al.
        Surgical advances in the management of brain metastases.
        Neurooncol Adv. 2021; 3: v4-v15
        • Olesrud I.C.
        • Schulz M.K.
        • Marcovic L.
        • et al.
        Early postoperative MRI after resection of brain metastases-complete tumour resection associated with prolonged survival.
        Acta Neurochir (Wien). 2019; 161: 555-565
        • Yoo H.
        • Kim Y.Z.
        • Nam B.H.
        • et al.
        Reduced local recurrence of a single brain metastasis through microscopic total resection.
        J Neurosurg. 2009; 110: 730-736
        • Junger S.T.
        • Pennig L.
        • Schodel P.
        • et al.
        The Debatable Benefit of Gross-Total Resection of Brain Metastases in a Comprehensive Treatment Setting.
        Cancers (Basel). 2021; : 13
        • Lee C.H.
        • Kim D.G.
        • Kim J.W.
        • et al.
        The role of surgical resection in the management of brain metastasis: a 17-year longitudinal study.
        Acta Neurochir (Wien). 2013; 155: 389-397
        • Liu Q.
        • Tong X.
        • Wang J.
        Management of brain metastases: history and the present.
        Chin Neurosurg J. 2019; 5: 1
        • Katz H.R.
        The relative effectiveness of radiation therapy, corticosteroids, and surgery in the management of melanoma metastatic to the central nervous system.
        Int J Radiat Oncol Biol Phys. 1981; 7: 897-906
        • Gaspar L.
        • Scott C.
        • Rotman M.
        • et al.
        Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials.
        Int J Radiat Oncol Biol Phys. 1997; 37: 745-751
        • Mulvenna P.
        • Nankivell M.
        • Barton R.
        • et al.
        Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial.
        Lancet. 2016; 388: 2004-2014
        • Brown P.D.
        • Gondi V.
        • Pugh S.
        • et al.
        Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001.
        J Clin Oncol. 2020; 38: 1019-1029
        • Brown P.D.
        • Pugh S.
        • Laack N.N.
        • et al.
        Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial.
        Neuro Oncol. 2013; 15: 1429-1437
        • Aoyama H.
        • Shirato H.
        • Tago M.
        • et al.
        Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.
        JAMA. 2006; 295: 2483-2491
        • Aoyama H.
        • Tago M.
        • Kato N.
        • et al.
        Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone.
        Int J Radiat Oncol Biol Phys. 2007; 68: 1388-1395
        • Brown P.D.
        • Jaeckle K.
        • Ballman K.V.
        • et al.
        Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial.
        JAMA. 2016; 316: 401-409
        • Hartgerink D.
        • Bruynzeel A.
        • Eekers D.
        • et al.
        A Dutch phase III randomized multicenter trial: whole brain radiotherapy versus stereotactic radiotherapy for 4-10 brain metastases.
        Neurooncol Adv. 2021; 3: vdab021
        • Li J.
        • Ludmir E.B.
        • Wang Y.
        • et al.
        Stereotactic Radiosurgery versus Whole-brain Radiation Therapy for Patients with 4-15 Brain Metastases: A Phase III Randomized Controlled Trial [abstract].
        Int J Radiat Oncol Biol Phys. 2020; 108: S21-S22
        • Cagney D.N.
        • Lamba N.
        • Montoya S.
        • et al.
        Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases.
        Breast Cancer Res Treat. 2019; 176: 171-179
        • Boogerd W.
        • Dalesio O.
        • Bais E.M.
        • et al.
        Response of brain metastases from breast cancer to systemic chemotherapy.
        Cancer. 1992; 69: 972-980
        • Spalek M.J.
        • Mandat T.
        Salvage Treatment for Progressive Brain Metastases in Breast Cancer.
        Cancers (Basel). 2022; 14
        • Dziadziuszko R.
        • Ardizzoni A.
        • Postmus P.E.
        • et al.
        Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965).
        Eur J Cancer. 2003; 39: 1271-1276
        • Cao K.I.
        • Lebas N.
        • Gerber S.
        • et al.
        Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer.
        Ann Oncol. 2015; 26: 89-94
        • Glantz M.J.
        • Cole B.F.
        • Recht L.
        • et al.
        High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?.
        J Clin Oncol. 1998; 16: 1561-1567
        • Kapke J.T.
        • Schneidewend R.J.
        • Jawa Z.A.
        • et al.
        High-dose intravenous methotrexate in the management of breast cancer with leptomeningeal disease: Case series and review of the literature.
        Hematol Oncol Stem Cell Ther. 2019; 12: 189-193
        • Cochereau D.
        • Da Costa S.
        • Le Maignan C.
        • et al.
        [Intrathecal methotrexate in breast cancer meningeal carcinomatosis - Experience with a new administration schedule].
        Bull Cancer. 2016; 103 (Methotrexate intrathecal dans les meningites carcinomateuses du cancer du sein - Experience avec le protocole utilise a l'hopital Saint-Louis): 444-454
        • Carausu M.
        • Carton M.
        • Darlix A.
        • et al.
        Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database.
        ESMO Open. 2021; 6: 100150
        • Pan Z.
        • Yang G.
        • He H.
        • et al.
        Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single-arm study.
        Int J Cancer. 2016; 139: 1864-1872
        • Mrugala M.M.
        • Kim B.
        • Sharma A.
        • et al.
        Phase II Study of Systemic High-dose Methotrexate and Intrathecal Liposomal Cytarabine for Treatment of Leptomeningeal Carcinomatosis From Breast Cancer.
        Clin Breast Cancer. 2019; 19: 311-316
        • Lin N.U.
        • Carey L.A.
        • Liu M.C.
        • et al.
        Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.
        J Clin Oncol. 2008; 26: 1993-1999
        • Lin N.U.
        • Dieras V.
        • Paul D.
        • et al.
        Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
        Clin Cancer Res. 2009; 15: 1452-1459
        • Lin N.U.
        • Eierman W.
        • Greil R.
        • et al.
        Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.
        J Neurooncol. 2011; 105: 613-620
        • Bachelot T.
        • Romieu G.
        • Campone M.
        • et al.
        Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.
        Lancet Oncol. 2013; 14: 64-71
        • Khan M.
        • Zhao Z.
        • Arooj S.
        • et al.
        Lapatinib Plus Local Radiation Therapy for Brain Metastases From HER-2 Positive Breast Cancer Patients and Role of Trastuzumab: A Systematic Review and Meta-Analysis.
        Front Oncol. 2020; 10: 576926
        • Kim I.A.
        • Winter K.
        • Sperduto P.
        • et al.
        CTNI-05. NRG Oncology/RTOG 1119: Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery with Concurent Lapatinib in Patients with Brain Metastases from HER2-positive Breast Cancer [abstract].
        Neuro Oncol. 2020; 22: ii42
        • Freedman R.A.
        • Gelman R.S.
        • Agar N.Y.R.
        • et al.
        Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022.
        Clin Breast Cancer. 2020; 20: 145-151 e2
        • Freedman R.A.
        • Gelman R.S.
        • Anders C.K.
        • et al.
        TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
        J Clin Oncol. 2019; 37: 1081-1089
        • Saura C.
        • Oliveira M.
        • Feng Y.H.
        • et al.
        Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With >/= 2 HER2-Directed Regimens: Phase III NALA Trial.
        J Clin Oncol. 2020; 38: 3138-3149
      2. Dinkel V, Anderson DH, Winski S, Winkler J, Koch K, Lee PA. ARRY-380, a potent, small molecule inhibitor of ErbB2, increases survival in intracranial ErbB2+ xenograft models in mice [abstract]. AACR 103rd Annual Meeting 2012-- Mar 31-Apr 4, 2012; Chicago, IL. 2012.

        • Cordero A.
        • Ramsey M.D.
        • Kanojia D.
        • et al.
        Combination of tucatinib and neural stem cells secreting anti-HER2 antibody prolongs survival of mice with metastatic brain cancer.
        Proc Natl Acad Sci U S A. 2022; : 119
        • Murthy R.K.
        • Loi S.
        • Okines A.
        • et al.
        Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
        N Engl J Med. 2020; 382: 597-609
        • Lin N.U.
        • Borges V.
        • Anders C.
        • et al.
        Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.
        J Clin Oncol. 2020; 38: 2610-2619
        • Curigliano G.
        • Mueller V.
        • Borges V.F.
        • et al.
        Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB) [abstract].
        J Clin Oncol. 2021; 39: 1043
        • Lin N.U.
        • Murthy R.K.
        • Abramson V.
        • et al.
        Abstract PD4-04: Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases (HER2CLIMB).
        Cancer Res. 2022; 82: PD4-PD05
        • Moja L.
        • Tagliabue L.
        • Balduzzi S.
        • et al.
        Trastuzumab containing regimens for early breast cancer.
        Cochrane Database Syst Rev. 2012; : CD006243
        • Musolino A.
        • Ciccolallo L.
        • Panebianco M.
        • et al.
        Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.
        Cancer. 2011; 117: 1837-1846
      3. Piccart M, Procter M, Fumagalli D, et al. Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): Aacr; Cancer Res 2020;80(4 Suppl):Abstract nr GS1-04.

        • von Minckwitz G.
        • Huang C.S.
        • Mano M.S.
        • et al.
        Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
        N Engl J Med. 2019; 380: 617-628
        • Stemmler H.J.
        • Schmitt M.
        • Willems A.
        • et al.
        Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.
        Anticancer Drugs. 2007; 18: 23-28
        • Lewis Phillips G.D.
        • Nishimura M.C.
        • Lacap J.A.
        • et al.
        Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis.
        Breast Cancer Res Treat. 2017; 164: 581-591
        • Lin N.U.
        • Pegram M.
        • Sahebjam S.
        • et al.
        Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study.
        J Clin Oncol. 2021; 39: 2667-2675
        • Zagouri F.
        • Zoumpourlis P.
        • Le Rhun E.
        • et al.
        Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression.
        Cancer Treat Rev. 2020; 88: 102046
        • Ratosa I.
        • Dobnikar N.
        • Bottosso M.
        • et al.
        Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real-world data from a multicentric European cohort.
        Int J Cancer. 2022;
        • Kumthekar P.
        • Lassman A.B.
        • Lin N.
        • et al.
        LPTO-02. Intrathecal (IT) Trastuzumab (T) for the Treatment of Leptomeningeal Disease (LM) in Patients (PTS) with Human Epidermal Receptor 2 Positive (HER2+) Cancer: A Multicenter Phase 1/2 Study [abstract].
        Neurooncol Adv. 2019; 1: i6
        • Bonneau C.
        • Paintaud G.
        • Tredan O.
        • et al.
        Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis.
        Eur J Cancer. 2018; 95: 75-84
        • Montemurro F.
        • Delaloge S.
        • Barrios C.H.
        • et al.
        Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial.
        Ann Oncol. 2020; 31: 1350-1358
      4. Hurvitz S, Kim SB, Chung WP, et al. Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03 [abstract], Cancer Res, 82 (4_supplement), 2022, GS3-01.

        • Jacobson A.
        Trastuzumab Deruxtecan Improves Progression-Free Survival and Intracranial Response in Patients with HER2-Positive Metastatic Breast Cancer and Brain Metastases.
        Oncologist. 2022; 27: S3-S4
        • Vaz Batista M.
        • Cortez P.
        • Ruiz M.
        • et al.
        Abstract PD4-06: Trastuzumab deruxtecan in patients with HER2[+] or HER2-low-expressing advanced breast cancer and central nervous system involvement: Preliminary results from the DEBBRAH phase 2 study.
        Cancer Res. 2022; 82: PD4-PD06
        • Bartsch R.
        • Berghoff A.S.
        • Furtner J.
        • et al.
        165MO - Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial [abstract].
        Ann Oncol. 2022; 33: S194-S223
        • Kabraji S.
        • Ni J.
        • Sammons S.
        • et al.
        Abstract PD4-05: Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases (BCBM).
        Cancer Res. 2022; 82: PD4-PD05
        • Kim L.S.
        • Huang S.
        • Lu W.
        • et al.
        Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice.
        Clin Exp Metastasis. 2004; 21: 107-118
      5. US Food and Drug Administration. Proposal to Withdraw Approval for the Breast Cancer Indication for AVASTIN (Bevacizumab).
        • Leone J.P.
        • Emblem K.E.
        • Weitz M.
        • et al.
        Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases.
        Breast Cancer Res. 2020; 22: 131
        • Lu Y.S.
        • Chen T.W.
        • Lin C.H.
        • et al.
        Bevacizumab preconditioning followed by Etoposide and Cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy.
        Clin Cancer Res. 2015; 21: 1851-1858
        • Berghoff A.S.
        • Breckwoldt M.O.
        • Riedemann L.
        • et al.
        Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases.
        Neurooncol Adv. 2020; 2: vdaa038
        • Liao G.
        • Khan M.
        • Zhao Z.
        • et al.
        Bevacizumab Treatment of Radiation-Induced Brain Necrosis: A Systematic Review.
        Front Oncol. 2021; 11: 593449
        • Tolaney S.M.
        • Sahebjam S.
        • Le Rhun E.
        • et al.
        A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer.
        Clin Cancer Res. 2020; 26: 5310-5319
        • Van Swearingen A.E.D.
        • Siegel M.B.
        • Deal A.M.
        • et al.
        LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.
        Breast Cancer Res Treat. 2018; 171: 637-648
        • Brenner A.J.
        • Pandey R.
        • Chiou J.
        • et al.
        Abstract PD13-05: Delivery and activity of SN-38 by sacituzumab govitecan in breast cancer brain metastases [asbtract].
        Cancer Res. 2021; 81 (PD13-05)
        • Batalini F.
        • Moulder S.L.
        • Winer E.P.
        • et al.
        Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib.
        JCO Precis Oncol. 2020; 4
        • Exman P.
        • Mallery R.M.
        • Lin N.U.
        • et al.
        Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis.
        NPJ Breast Cancer. 2019; 5: 46
        • Smith A.E.
        • Ferraro E.
        • Safonov A.
        • et al.
        HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway.
        Nat Commun. 2021; 12: 6667